title: Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
authors.affiliation: Department of Hematology, Medical University of Vienna, Vienna, Austria.
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
authors.forename: Martin
authors.initials: M
authors.lastname: Schalling
authors.forename: Bettina
authors.initials: B
authors.lastname: Gisslinger
authors.forename: Cathrin
authors.initials: C
authors.lastname: Skrabs
authors.forename: Leonhard
authors.initials: L
authors.lastname: Müllauer
authors.forename: Robert
authors.initials: R
authors.lastname: Kralovics
mesh_terms: D000368:Aged; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics; D008875:Middle Aged; D009570:Nitriles; D009929:Organ Size / Q000187:drug effects; D011087:Polycythemia Vera / Q000150:complications; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D028761:Withholding Treatment
chemical_list: D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2